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Resumen
Los anticonceptivos reversibles de larga duración o LARC (por sus siglas en inglés Long-Acting Reversible Contra-
ception) son métodos altamente efectivos aptos para la mayoría de las mujeres. El dispositivo intrauterino de 
cobre (DIU-Cu) y el hormonal, con levonorgestrel (DIU-LNG), pese a ser los anticonceptivos reversibles de larga 
duración más conocidos, son usados en España por el 6,9% de las mujeres en edad fértil que usa algún método. Se 
cree que esto responde a barreras al uso de dispositivos intrauterinos existentes entre los profesionales sanitarios 
que afectarían especialmente a mujeres jóvenes y/o nulíparas. En la presente revisión se aborda la evidencia 
disponible sobre los principales aspectos que generan una barrera al uso de los dispositivos intrauterinos. Estos 
aspectos incluyen las posibles dificultades durante su inserción y el dolor que esta puede causar, el riesgo de 
perforación durante la inserción o de expulsión una vez insertado, el efecto sobre la dismenorrea y el patrón de 
sangrado menstrual, el riesgo de embarazo ectópico o de enfermedad inflamatoria pélvica, la rapidez de recu-
peración de la fertilidad tras la retirada, el impacto del precio y la relación coste-beneficio de estos métodos. 
Igualmente, se aborda la barrera que puede suponer el posible rechazo al uso del dispositivo intrauterino por 
parte de la mujer a consecuencia de creencias erróneas. 
Abstract
Long-acting reversible contraception (LARC) refers to highly effective methods that are suitable for most 
women. Despite being the best known long-acting reversible contraception methods, the copper intrauterine 
device (Cu-IUD) and the hormonal (levonorgestrel) device (LNG-IUD) are used by only 6.9% of women of 
childbearing age in Spain who use any method of contraception. This may be a consequence of barriers to 
the use of IUDs among health professionals that affect young and/or nulliparous women in particular. The 
present review addresses available scientific evidence regarding the main factors creating barriers to the 
use of intrauterine devices. These factors include possible difficulties during insertion and associated pain, 
the risk of perforation during the insertion or of expulsion once inserted, the effects on dysmenorrhoea and 
on menstrual bleeding pattern, the risk of ectopic pregnancy or of pelvic inflammatory disease, the speed 
of recovery of fertility after removal, the impact of price, and the cost-benefit ratio of intrauterine devices. 
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INTRODUCTION
Unplanned pregnancy remains a serious problem in 
Spain, especially among young women (1). The main 
contraceptives used by this population include the con-
dom and the pill (2), both of which depend to a large 
extent on adherence, thus reducing their effectiveness 
(3). Long-acting reversible contraception (LARC) refers to 
methods that are recommended by international medical 
societies for women who require effective contraception, 
including young women, provided that there are no spe-
cific contraindications (4,5). Since these methods do not 
depend on the active participation of the users, they are 
highly effective (low Pearl index or number of unplanned 
pregnancies per 100 women and year) (5) and provide 
long-lasting contraceptive protection for as long as the 
user wishes (6,7). Furthermore, most women can use this 
approach, even adolescents (8).
The copper IUD (Cu-IUD) and the hormonal device 
with levonorgestrel (LNG-IUD) are the most widely used 
methods in Spain and neighboring countries (9,10). Howe-
ver, the IUD is not very widely used in Spain, given that 
it is the preferred method in only 6.9% of fertile women 
who use a contraceptive method (2). This is in part due to 
barriers between health professionals that mainly affect 
young and/or nulliparous women. Young women make up 
a group with a high rate of unplanned pregnancies in Spain 
(11,12) and in which LARC could be particularly beneficial 
(5,13,14). Currently marketed approaches include various 
types of Cu-IUD device with different copper levels and 
sizes and 2 LNG-IUD devices with different hormonal levels 
and sizes (52 mg of LNG and 32 x 32 mm vs 13.5 mg and 
28 x 30 mm). This variety enables better adaptation to 
the needs and preferences of the individual user while 
offering an opportunity to overcome barriers to use. 
The present review addresses available evidence on the 
main barriers to the use of IUDs, many of which affect 
young and/or nulliparous women in particular. These 
barriers include possible difficulties during insertion and 
potential associated pain, the risk of perforation during 
insertion or expulsion after insertion, the effect on dys-
menorrhea and menstrual bleeding pattern, the risk of 
ectopic pregnancy or pelvic inflammatory disease (PID), 
the speed of recovery of fertility after withdrawal, the 
impact of price, and the cost-benefit ratio. Similarly, we 
analyze the barrier to recommendation of these methods 
constituted by the possible rejection of the IUD by the 
user based on misconceptions. 
BARRIER 1: INSERTION OF THE INTRAUTERINE 
DEVICE CAN BE DIFFICULT AND PAINFUL 
One of the main barriers to more widespread use of 
IUDs is the belief that the insertion process is difficult and 
painful, both during insertion and afterwards. This barrier 
is particularly important in the case of adolescent women, 
since they have a smaller endometrial cavity, and in the 
case of nulliparous women, since they have a narrower 
cervix (15).
Evidence on the difficulty of inserting an IUD in nullipa-
rous women shows that the rate of failed insertion is very 
low. One study in Sweden and Finland found that inser-
tion failed in 2.1% of cases (16); this finding was similar to 
that reported from a subsequent study in Sweden (2.7%), 
where insertion was performed mainly by midwives (17). 
Insertion was considered easy in 85% of cases in the first 
study and in 72% of cases in the second (16,17). 
Few data are available to compare pain during insertion 
in nulliparous women and in women who have undergone 
vaginal delivery. In a study of 2,019 women who recei-
ved their first Cu-IUD, pain was generally mild, although 
somewhat more severe in nulliparous than in multiparous 
women (mean, 2.7 cm vs 1.9 cm, respectively, on a 10-cm 
visual analog scale) 18). 
At present, smaller IUDs, in which the insertion tube is 
smaller in diameter, could go some way to overcoming the 
fear of a difficult or painful insertion. This aspect is reflec-
ted in the results of a phase II trial comparing the efficacy 
and safety profile of a larger LNG-IUD with a higher hor-
monal load (32 x 32 mm, 52 mg; Mirena®, Bayer) with 
the smaller size and lower hormonal level of a currently 
marketed device (28 x 30 mm, 13.5 mg; Jaydess®, Bayer) 
and another LNG-IUD of the same size but with an inter-
mediate hormonal level (19.5 mg, not marketed). Overall, 
98.5% of insertions were successful at the first attempt. 
The researchers classed the insertion as easy in 94.0% 
of those women who used the 13.5-mg/19.5-mg device, 
compared with 86.2% of those who used the 52-mg devi-
ce (p < 0.001). In the case of the 13.5-mg/19.5-mg device, 
72.3% of the women felt that the insertion was not painful 
or that it caused mild pain compared with 57.9% of tho-
se who used the 52-mg device (19). The 52-mg device 
is currently marketed in Europe as Evoinserter™, which 
has an insertion tube with a smaller diameter. A phase III 
study that evaluated the efficacy and safety profile of the 
13.5- mg and 19.5-mg devices found that 99.5% of inser-
tions were successful and that 89.6% were considered 
easy (20) (94.5% in women who had had a vaginal deli-
very vs 84.2% in nulliparous women) (21). A study of the 
13.5-mg device in adolescents (12-17 years) showed that 
insertion was successful in 99.7% of cases. The insertion 
was considered easy in 94.4% and painless or moderately 
painful in 89% (22). 
In addition to the size of the IUD, the experience of the 
health professional with insertion is essential, since it has 
been shown that the initial degree of difficulty perceived 
diminishes with experience (20,23-25). As for the effect 
of pharmacological measures on insertion-related pain, 
a review showed that evidence supporting this approach 
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was lacking (26). Nevertheless, while misoprostol has not 
proven able to reduce the pain associated with insertion, 
it has been shown to make the procedure easier (27). 
BARRIER 2: THERE IS A RISK OF PERFORATION 
DURING INSERTION OF THE INTRAUTERINE DEVICE 
The risk of perforation during insertion of an IUD is 
very low (~1 of every 1,000 insertions) (28,29), with no 
differences between the 2 types of IUD (29). The fear of 
perforation is greater in nulliparous women owing to the 
smaller size of their uterine cavity and greater resistance 
of the cervix to dilation. However, while scarce, evidence 
on the risk of perforation in nulliparous women shows that 
there is no greater risk with respect to women who have 
already given birth (17,21,30,31). In contrast, breastfee-
ding during insertion has been associated with a risk of 
perforation that is almost 6 times greater (29).
BARRIER 3: THE INTRAUTERINE DEVICE CAN BE 
EXPELLED AFTER INSERTION
The risk of an IUD being expelled after insertion is low: 1 
in every 20 women in 5 years (28). Available annual rates 
do not exceed 6%(23, 30-33). While the risk of expulsion 
is thought to be greater in nulliparous women, current 
evidence does not support this belief (23, 32-37). The 
Cu-IUD is associated with a greater risk of expulsion than 
the LNG-IUD (33), especially in nulliparous women (38). 
A phase II study that compared LNG-IUD of different sizes 
and hormonal levels found the expulsion rate at 36 mon-
ths to be 1.6% for the 52-mg device and 0.4% for the 13.5-
mg device (19). In a phase III study, the cumulative rate of 
expulsion for the 13.5-mg device at 3 years was 4.6% (20).
BARRIER 4: INTRAUTERINE DEVICES CAUSE 
DYSMENORRHEA 
A limited number of women (< 10%) may experience 
episodes of dysmenorrhea when using contraceptives, 
including IUDs, although these are usually transient and 
moderate (39-43). The possibility of dysmenorrhea advi-
ses against using the IUD in women who already have the 
condition, although dysmenorrhea is not normally a con-
traindication for use (39,41,44). 
Available evidence indicates that because of their hor-
monal level, LNG-IUDs may help to relieve dysmenorrhea. 
At the end of the phase II study (3 years) comparing the 
LNG-IUDs mentioned above, the percentage of women 
without dysmenorrhea increased from 49.9% to 82.0% 
with the 13.5-mg device and from 43.7% to 83.7% with 
the 52-mg device (19). A study of adolescent women using 
the 13.5-mg device showed that the percentage without 
dysmenorrhea increased from 38% to 62% at the end of 
the first year (22). This effect seems to be based on anti-
proliferative action, induction of glandular atrophy, and 
decidualization of endometrial tissue by LNG, all of which 
considerably reduce bleeding (45). This beneficial effect 
cannot be extrapolated to the Cu-IUD. 
BARRIER 5: INTRAUTERINE DEVICES LEAD TO 
CHANGES IN MENSTRUAL BLEEDING PATTERN
The change in bleeding pattern after insertion of an 
IUD is very important, since it is one of the main reasons 
a user discontinues the method (5,6). The effect on the 
bleeding pattern is different for both types of IUD. The 
adverse effects of the Cu-IUD include intermenstrual blee-
ding during the first month and a moderate increase in the 
intensity and duration of bleeding (46). In contrast, use of 
the 52-mg device is associated with a gradual reduction in 
menstrual bleeding to the extent that at 6 months, 25% 
of women presented some degree of spotting and 44% 
amenorrhea (47). 
The bleeding pattern should be evaluated before 
inserting an IUD. It is also important to determine whe-
ther the woman experiences heavy menstrual bleeding 
(blood loss >80 mL per cycle), since this affects the choi-
ce of device. The 52-mg device has been the treatment 
of choice for heavy bleeding for more than a decade 
(48,49). The number of days of bleeding and spotting 
decreases and the frequency of amenorrhea increa-
ses with the duration of use (maximum 3 years) of the 
13.5-mg device (Fig. 1) (19). However, the frequency 
of amenorrhea after 1 year with the 13.5-mg device is 
lower than that observed with the 52-mg device, ranging 
from 2.7% to 12.7% and from 5.9% to 23.6%, respecti-
vely, measured at the second and last 90-day reference 
period (p=0.012) (19).
Changes in bleeding pattern have an important effect on 
the degree of satisfaction with the method used. Ameno-
rrhea can be seen positively (no menstruation-associated 
discomfort) (50) or negatively (loss of femininity or ferti-
lity or the possibility of pregnancy) (51). In the phase III 
study with the 13.5-mg device, most of the women who 
used it (76.4%) were satisfied or very satisfied with their 
bleeding pattern, and only 4.7% discontinued the method 
because of changes in bleeding pattern at the end of the 
third year (20).
BARRIER 6: INTRAUTERINE DEVICES INCREASE THE 
RISK OF ECTOPIC PREGNANCY
The risk of ectopic pregnancy is yet another major 
concern on the part of health professionals when 
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recommending IUDs (15). Of the infrequent pregnan-
cies that do occur in IUD users, a high proportion are 
ectopic (6% vs 1.4% in women who do not use contra-
ceptives) (5). The risk increases in inverse proportion 
to the copper or hormone level (52-55). Therefore, 
although the relative risk of an ectopic pregnancy is 
greater, the absolute risk is very low (1/1,000 users in 
5 years) owing to the high efficacy of the method (5). 
Table I shows the different rates for ectopic pregnancy 
compared with oral contraception or not using contra-
ception (45). A history of ectopic pregnancy does not 
contraindicate use of an IUD (8).
BARRIER 7: INTRAUTERINE DEVICES CAN CAUSE 
PELVIC INFLAMMATORY DISEASE 
Infection by Chlamydia trachomatis is the most com-
mon sexually transmitted infection in Europe and the main 
cause of PID, which can lead to loss of fertility. There is a 
belief that inserting an IUD, regardless of the type, carries 
a permanent risk of PID. This belief particularly affects 
nulliparous women (15,56), especially if they are single 
or have multiple sexual partners (56), thus indicating that 
this fear is founded more on possible risky sexual beha-
viors than on greater susceptibility to PID. 
A review of clinical trials on IUDs by the World Health 
Organization (WHO) has shown that the global inci-
dence of PID among the 22,908 insertions and 51,399 
women-years of follow-up included in the trials was 1.6 
cases per 1,000 women-years of use (57). After adjus-
ting for confounders, the risk of PID was found to be 6 
times greater during the first 20 days after insertion, 
whereas it was low and constant during the 8 years 
of follow-up (57). This suggests that the pathogenesis 
of PID in the first 20 days after insertion is associated 
with the transmission of pathogenic bacteria (C. tra-
chomatis, Neisseria gonorrhoeae) that cause asympto-
matic infections when the device is fitted. Therefore, 
it is important to identify signs of vaginitis or cervicitis 
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Figure 1. Mean number of days with menstrual bleeding or spotting by 90-day reference period for 3 years using the LNG-IUD 13.5 mg (reference periods 
1-12). Adapted from Gemzell-Danielsson et al. 2012 (19). Reproduced with the authors’ permission. Cu-IUD, copper intrauterine device; LNG-IUD, intrau-
terine device with levonorgestrel.
Table I.








No methods (25-34 y) 7.5-10.6
Adapted from Gutiérrez et al. 2014 (45).
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the device in women at a high risk of sexually transmit-
ted infections, even if they do not present symptoms 
(58,59). The IUD can be inserted on the same day, with-
out waiting for test results. If the test result is positive, 
treatment can be initiated with the IUD already fitted 
(59). In any case, a recent systematic review (2016) of 
2 studies in which an IUD was fitted in women with 
positive results for both pathogens on insertion showed 
that the rate of PID was not greater than that of women 
who opted for other methods (60). 
A study performed over 3 years in more than 2,500 users 
of the Cu-IUD or LNG-IUD revealed that the cumulative rate 
of PID with the Cu-IUD was similar to that of women who 
did not use the PID, whereas with the LNG-DIU (52 mg) 
it was even lower (2.0 vs 0.5; p < 0.013) (61). This result 
indicates that the LNG-IUD would have a protective effect 
on the development of PID. This effect could be due to its 
mechanism of action, so that thickening of the cervical 
mucus, which hampers the passage of sperm cells to the 
uterus, would also hamper the passage of bacteria (61). 
BARRIER 8: WE DO NOT KNOW HOW LONG IT 
TAKES TO REGAIN FERTILITY AFTER WITHDRAWAL 
OF THE INTRAUTERINE DEVICE
Despite including a limited number of women, studies 
that have analyzed the impact of withdrawal of the IUD 
on fertility consistently show that fertility is recovered 
quickly and effectively (62). The studies also show that 
the rate of pregnancy after withdrawal is generally high 
and similar to that of the general population and that the 
causes of infertility are the same. Recovery of fertility is 
quick, even in women whose IUD was withdrawn owing 
to complications. The birth rate was shown to be high. In 
addition, normal results were recorded for preterm births, 
birth weight, and sex ratios in newborns (62). 
A study of 2,841 women using contraceptives showed 
that the long-term use of combined oral contracepti-
ves, injectable contraceptives, or Cu-IUD has a negati-
ve effect on fertility (time taken to become pregnant), 
which depends on the duration of use. In contrast, the 
progestin pill alone or the LNG-IUD 52-mg device had no 
significant effect: all of the users of the LNG-IUD whose 
device was withdrawn owing to the desire to become 
pregnant became pregnant within 1 month (63). The 
effect with the Cu-IUD on fertility was also demonstrated 
in a retrospective study performed in 2013. The authors 
analyzed 1,770 Chinese women—some of whom were 
older (mean age, 37.3 (5) years; range, 21-53 years)—
who had lost children in the 2008 earthquake and who 
had opted for withdrawal of the Cu-IUD in order to beco-
me pregnant. The results showed that, even though the 
rate of pregnancy after withdrawal was high (80.1%), 
it fell in inverse proportion to time with the Cu-IUD to 
stand at 89.8% in those who had used the device for 
under 5 years and from 81.1% and 75.2% in those who 
used it, respectively, for 6-10 years and >10 years. Of 
those who conceived, 88% did so before the end of the 
first year (64).
Studies carried out in users of the 52-mg device showed 
that after withdrawal, the endometrium recovers rapidly, 
ovulation is re-established, and fertility remains unchan-
ged (65,66). The rate of pregnancy at 2 years was similar 
to that of the general population (86.6%), and 96% of 
women became pregnant during the first year (65). The 
time using the LNG-IUD did not affect the subsequent rate 
of pregnancy (66).
A review of 17 prospective studies that provided data on 
the rate of pregnancy after discontinuation of the contra-
ceptive method showed that after use of oral contracepti-
ves or the 52-mg device, the pregnancy rate at 1 year was 
79-96%, whereas with the Cu-IUD it was 71-91%. These 
rates are similar to those reported after discontinuation 
of barrier methods and to those reported in women who 
did not use contraception. No increase in complications 
associated with pregnancy or adverse fetal outcomes was 
reported (67). 
BARRIER 9: INTRAUTERINE DEVICES ARE 
EXPENSIVE 
Although the initial cost of the IUD and its insertion 
is higher than that of a short-term method, the cost of 
the IUD diminishes with each year of use, since, once 
inserted, it requires no additional expenditure. According 
to the National Institute for Health and Care Excellen-
ce (NICE), the 4 LARC methods are more cost-effective, 
even after 1 year of use, than short-term methods such 
as combined oral contraceptives. Of the LARC methods 
used, IUDs and implants are more cost-effective than 
injectable methods (5). 
A study of 1,000 women aged 20-29 years carried 
out in 2015 in the USA compared the cost-effective-
ness of not using any contraceptive method, using LARC 
(Cu-IUD, LNG-IUD 52 mg, or implant), or using a short-
term method (oral contraception, vaginal ring, patch, 
injectable contraceptive) over 5 years. The authors 
found that the Cu-IUD and LNG-IUD had to be used 
for at least 2.1 years for them to generate savings with 
respect to the use of short-term methods and 3 years 
with respect to condoms (68). Figure 2 shows the costs 
of each option studied. A similar study comparing the 
cost-effectiveness of LNG-IUD 13.5 mg with that of the 
same short-term methods in 1,000 women aged 20.29 
years over 3 years showed that the former resulted in 
fewer unplanned pregnancies (64 vs 276) and a lower 
total cost (US$1,283.5 vs US$1,862.6), with a saving of 
31% over the 3 years(69).
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Table II.
Recommendations for improving the information provided to women for each of the barriers to using an IUD
1. Insertion of the IUD can be difficult and painful
• Provide the patient with detailed information on the insertion procedure: time, preparation, potential discomfort/pain during and after 
insertion, time to recovery of activities of daily living.
• Quantify perceived pain in comparison with the patient’s experience (period pain, placement of piercings, etc). 
•  Provide positive information: tell the patient about the high percentage of successful insertions, as well as about women who do not feel 
pain or in whom pain is mild or moderate.
• Avoid negative expressions such as "Only a small percentage of women feel pain" or "The first insertion fails in only a small percentage of 
women".
• Make every effort to relieve potential anxiety. Provide measures for managing pain if it arises.
2. There is a risk of perforation during insertion of the IUD
• Be positive when informing the patient about the low frequency of perforation. 
• Dispel the idea that perforation is more frequent in nulliparous women. 
• Indicate warning signs that are suggestive of perforation and provide guidelines.
3. The IUD can be expelled after insertion
• Be positive when informing the patient about the low frequency of expulsion.
• Dispel the idea that perforation is more frequent in nulliparous women.
• Indicate warning signs that are suggestive of expulsion and provide guidelines.
4. IUDs cause dysmenorrhea
• When taking the history and providing advice on contraception, ask the patient about period pain and her perception of how this affects 
her activities of daily living and quality of life.
• Inform the patient that in addition to the effectiveness of this method, the LNG-IUD can lead to a marked improvement in pain associated 
with menstruation.
• Explain in a comprehensible way how this effect is achieved. 
5. IUDs lead to changes in menstrual bleeding pattern
• Together with the patient, evaluate the bleeding pattern before insertion of an IUD.
• Explain the bleeding pattern that is characteristic of each type of IUD.
• Together with the patient, analyze the reasons for and benefits of reducing bleeding and amenorrhea.
6. IUDs increase the risk of ectopic pregnancy
•  Provide advice on the effectiveness of all types of contraception.
• Always inform the patient about the risk of ectopic pregnancy in absolute terms and compare the rate of ectopic pregnancy with the IUD, 
other contraceptive methods, or no contraceptive methods.
• Indicate warning signs that are suggestive of ectopic pregnancy and provide guidelines.
7. IUDs can cause pelvic inflammatory disease
• Take a clinical history and perform a physical examination to rule out signs and behaviors that point to a high risk of sexually transmitted 
infection.
•  Inform the patient about routes of contagion by sexually transmitted diseases and advise her to combine the IUD with condoms in order to 
prevent infection.
• Indicate warning signs that are suggestive of pelvic inflammatory disease and provide guidelines.
8. We do not know how long it takes to regain fertility after withdrawal of the IUD
• Inform the patient about the immediate recovery of fertility after withdrawal of the IUD.
• Provide appropriate information on the useful life of each device and of the option to withdraw it before the end of the useful life.
•  Provide guidelines on withdrawal of the IUD:
- If contraception is required, begin immediately.
- If the patient wishes to become pregnant, take preconception measures.
9. IUDs are expensive
• Provide advice on all contraceptive methods irrespective of the woman’s financial situation.
•  Inform the patient about the cost of each method over comparable time periods (annual cost, 3 years, 5 years).
• Together with the patient, analyze the costs associated with the use of each method:
- Costs associated with visits to the doctor.
- Costs associated with the use of sanitary napkins or other hygiene methods.
- Time taken and frequency of visiting the doctor/pharmacy.
- Costs associated with the use of analgesia (where applicable).
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BARRIER 10: WOMEN ARE UNWILLING TO USE THE 
INTRAUTERINE DEVICE
The lack of knowledge about the various contraceptive 
methods among women, which is the result of inade-
quate sex education, encourages misconceptions about 
contraceptives in general or about specific methods in 
particular. The negative attitudes generated lead some 
women not to use any method or discontinue/change 
their current method, thus causing the recommendation 
to be passed on to other women (70,71). 
Advice on contraception by health professionals and 
the way information is presented have been shown 
to play a key role in the decision taken by the woman 
(72-74). Advice on contraception is also relevant, since 
the user’s satisfaction with the method chosen and its 
eventual success depend on adequate knowledge and 
perception of the method (5). Women who do not know 
the effectiveness and safety of LARC, women who do not 
receive appropriate information, and women with mis-
conceptions about the various methods cannot use this 
approach as a contraceptive method, thus increasing the 
possibility of them using less effective methods. Several 
studies have shown that once a woman has heard about 
LARC methods, she is interested in learning more about 
them (75-78). 
Women, even adolescent and nulliparous women, 
should be informed that LARC is the best approach to 
contraception in most cases. Various international socie-
ties recommend informing users about LARC when advice 
on contraception is provided, even if the potential user 
requests or shows a preference for another method (4,28). 
Advice should include the advantages of LARC methods, 
namely, their high effectiveness regardless of motivation 
and adherence, good continuation rates, and the high 
degree of satisfaction among users. It should be highligh-
ted that the methods are reversible and that, when they 
are withdrawn, fertility is regained quickly. Similarly, the 
methods are cost-effective and have few contraindications 
(5,79). We must counter misconceptions about IUDs, 
many of which are influenced by the beliefs of the health 
professional, probably owing to the negative attitude of 
the professional toward the use of the IUD, especially in 
young and nulliparous women. Table II presents a series 
of recommendations for health professionals to help them 
provide appropriate advice on each of the barriers to the 
use of the IUD.
In order to favor use of the IUD, guidelines recommend 
facilitating insertion on the day the patient seeks advice 
on contraception where possible and if pregnancy can be 
reasonably ruled out (5,79).
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